腺苷脱氨酶重症联合免疫缺陷基因治疗的长期结局
10例ADA SCID患者接受MND-ADA γ逆转录病毒载体修饰的自体CD34+细胞输注,经白消安减强度预处理后随访8-11年。9/10例免疫重建足以防御严重感染,无需恢复ERT或二次异基因HSCT;4/9例停用免疫球蛋白替代且对疫苗应答。年轻患者及接受更高基因标记CD34+细胞剂量者结局更好,未观察到白血病增殖事件但存在持续克隆。
要点
- 9/10例ADA SCID患者基因治疗后8-11年免疫重建足以防御严重感染,无需ERT或二次HSCT。
- 4/9例可评估患者停用免疫球蛋白替代且对疫苗应答。
- 年轻患者和接受更高基因标记CD34+细胞剂量者结局更好。
核心结论
- 基因治疗对ADA SCID具有持久疗效,但γ逆转录病毒载体存在基因毒性风险。
研究设计与样本
- 2期临床试验纳入10例ADA SCID患者,年龄3个月至15岁,2009至2012年接受基因治疗,长期随访8至11年。
- 自体骨髓CD34+细胞经MND-ADA γ逆转录病毒载体体外转导,白消安减强度预处理后回输。
主要发现
- 9/10例患者免疫重建足以防御严重感染,未恢复ERT或进行二次异基因HSCT。
- 最年长患者基因治疗后6个月因无获益恢复ERT。
- 4/9例可评估患者(基因标记和B细胞数最高)停用免疫球蛋白替代并对疫苗应答。
- ADA酶活性、腺嘌呤代谢物及细胞和体液免疫重建正常化程度范围宽。
- 年轻患者及接受更高剂量基因标记CD34+细胞者结局总体更好。
临床怎么用
- 基因治疗可作为ADA SCID的治疗选择,尤其对年轻患者。
- 需长期监测基因毒性相关克隆和免疫重建。
局限性
- 样本量小(10例),随访8至11年。
- γ逆转录病毒载体存在基因毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients lacking functional adenosine deaminase activity have severe combined immunodeficiency (ADA SCID), which can be treated with ADA enzyme replacement therapy (ERT), allogeneic hematopoietic stem cell transplantation (HSCT), or autologous HSCT with gene-corrected cells (gene therapy [GT]). A cohort of 10 ADA SCID patients, aged 3 months to 15 years, underwent GT in a phase 2 clinical trial between 2009 and 2012. Autologous bone marrow CD34+ cells were transduced ex vivo with the MND (myeloproliferative sarcoma virus, negative control region deleted, dl587rev primer binding site)-ADA gammaretroviral vector (gRV) and infused following busulfan reduced-intensity conditioning. These patients were monitored in a long-term follow-up protocol over 8 to 11 years. Nine of 10 patients have sufficient immune reconstitution to protect against serious infections and have not needed to resume ERT or proceed to secondary allogeneic HSCT. ERT was restarted 6 months after GT in the oldest patient who had no evidence of benefit from GT. Four of 9 evaluable patients with the highest gene marking and B-cell numbers remain off immunoglobulin replacement therapy and responded to vaccines. There were broad ranges of responses in normalization of ADA enzyme activity and adenine metabolites in blood cells and levels of cellular and humoral immune reconstitution. Outcomes were generally better in younger patients and those receiving higher doses of gene-marked CD34+ cells. No patient experienced a leukoproliferative event after GT, despite persisting prominent clones with vector integrations adjacent to proto-oncogenes. These long-term findings demonstrate enduring efficacy of GT for ADA SCID but also highlight risks of genotoxicity with gRVs. This trial was registered at www.clinicaltrials.gov as #NCT00794508.
引用
- Reinhardt B, Habib O, Shaw KL, et al. Long-term outcomes after gene therapy for adenosine deaminase severe combined immune deficiency. Blood. 2021. PMID: 33974038. doi:10.1182/blood.2020010260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。